![E3353_06 [ALT4bxxx].png](https://static.wixstatic.com/media/73af19_0b90f98cbdf94c8b808d8ee2921668a0~mv2.png/v1/fill/w_921,h_928,al_c,q_90,usm_0.66_1.00_0.01,enc_auto/E3353_06%20%5BALT4bxxx%5D.png)
Join us on
our journey to
beat cancer
Etcembly is committed to transforming cancer treatment through innovative research and technology. Together, we can make a difference in the fight against cancer.
​
We invite researchers, clinicians, and stakeholders in the field of oncology to collaborate with us. Together, we can unlock the potential of immune repertoire analysis and make strides in the development of next-generation immunotherapies.
For more information about our projects and how you can get involved, please contact us at: info@etcembly.com
OUR TEAM
Michelle Teng
CEO Co-founder
​
20 years of R&D experience covering pipeline from discovery to translational medicine in Immunocore & AstraZeneca
Jacob Hurst
CTO Co-founder
25 years of experience in translational medicine, TCR and antibody repertoire analytics
Nick Pumphrey
CSO
Over 20 years of experience developing TCR-based therapeutics at Immunocore and Adaptimmune
Scott Cuthill
CBO
25 years of experience in
Pharma Biotech sector including senior BD roles in Chroma Therapeutics, Ipsen and ValoTx
Beckie Bown
CFO
Over 20 years of finance experience in biotech/pharma, including supporting financing transactions and collaborative arrangements
John McCafferty
Scientific Advisor
Serial entrepreneur. Founder of Cambridge Antibody Technology, Maxion Therapeutics and IonTas
Tom Holdich
Consulting CMO
Physician with 37 years’ industry experience of drug development, the last 10 years in TCR T-cell therapy at Adaptimmune and consulting for other Biotechs
Christopher Buckley
Clinical Advisor
Kennedy Professor of Translational Rheumatology at the University of Oxford, and Director of Clinical Research at the Kennedy Institute of Rheumatology
Nick Cross
Chairman
Serial founder and investor with considerable Board experience, including Immunocore, Adaptimmune, Oxford Asymmetry and Oxford Semiconductor Ltd
Bent Jakobsen
Director
TCR therapies pioneer.
Founded Immunocore and Adaptimmune
PARTNERS
CONTACT
​
If you are as excited about our journey as
we are, then please drop us an email.
CAREERS
​
We are committed to developing the next generation of scientists and welcome motivated individuals who share our vision. If you aspire to break boundaries in precision medicine and are able to demonstrate understanding in the convergence of these fields, we are interested in hearing from you.​​
